We analyzed the quantity of S100A4, S100A8, S100A9, and S100A12 immunopositive MNCs and CD19+ cells in CLL patients regardless of genetic abnormalities. This evidence concerns the gene S100A8 and B-cell chronic lymphocytic leukemia.